誰も教えてくれなかった　循環器薬の選び方と使い分け　第2版

出版社： 総合医学社
著者：
発行日： 2020-02-10
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784883786923
電子書籍版： 2020-02-10 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：約3営業日

3,300 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,300 円(税込)

購入する

商品紹介

血管拡張薬や強心薬の使い分け、薬剤抵抗性高血圧の次の一手、心室性不整脈に対する抗不整脈薬の選択の仕方など、複数の循環器薬の選び方と使い分け方を、理由とともに解説。治療の分岐点に立ったときのヒントが満載。

目次

  • Part1　心不全
    　1．血管拡張薬の使い分け
    　2．強心薬（カテコラミン）の使い分け
    　3．利尿薬（Na利尿薬と非Na利尿薬)の使い分け
    　4．PDEIII阻害薬はどう使うのか？
    　5．ACE阻害薬とARBの使い分け
    　6．βブロッカーの使い分け
    　7．心不全におけるジギタリスの使い方

    Part2　虚血性心疾患
    　1．慢性冠動脈疾患のベーシック治療は？
    　2．高力価硝酸薬と低力価硝酸薬の使い分け
    　3．スタチン通常量で効果不十分のときはどうするのか？
    　4．抗酸化療法の考え方

    Part3　高血圧
    　1．最初に処方する降圧薬をどう選択するのか？
    　2．積極的適応がない場合の降圧薬の選択
    　3．併用薬の選び方
    　4．薬剤抵抗性高血圧の次の一手は？

    Part4　不整脈
    　1．I群薬の選択の仕方
    　2．心室性不整脈に対する抗不整脈薬の選択の仕方
    　3．発作性上室性頻拍（PSVT）発作時の静注薬の選択
    　4．心房細動の治療
    　5．心房細動のレートコントロール
    　6．急性心筋梗塞時の不整脈予防

    Part5　血栓塞栓症
    　1．血栓塞栓症の治療薬
    　2．抗凝固薬の選択
    　3．ステント留置後の抗血小板薬使用
    　4．抗血小板薬と抗凝固薬の併用
    　5．DOACsの使い分け

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 心不全

P.36 掲載の参考文献
1) Yancy CW, et al:Safety and efficacy of outpatient nesiritide in patients with advanced heart failure. Results of the second follow-up serial infusions of nesiritide(FUSION II) trial. Circ Heart Fail 2008;1(1):9-16.
PubMed
2) Loeb HS, et al:Superioroty of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure. Circulation 1997;55:375-381.
 
3) Backer DD, et al:Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362.
 
4) Abraham WT, et al:In-hospital moratality in patients with acute decompensated heart failure requiring intravenous vasoactive medications. An analysis from the Acute Decompensated Heart Failure National Registry(ADHERE). J Am Coll Cardiol 2005;46:57-64.
 
5) Cuff e MS, et al:Short-term intravenous milrinone for acute exacerbation of chronic heart failure. A randomized controlled trial. JAMA 2002;287:1541-1547.
 
6) Savarese G, et al:A meta-analysis reporting eff ects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013;61:131-142.
 
7) Waagstein F, et al:Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in dilated cardiomyopathy (MDC) trial study group. Lancet 1993;342:1441-1446.
 
8) CIBIC-II Investigators and Commettees:The cardiac insuffi ciency bisoprolol study II(CIBIS-II):a randomized trial. Lancet 1999;353:9-13.
 
9) Hori M, et al:Low-dose carvediolol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure:The multicenter carvedilol heart failure dose assessment (MUCHA) trial. Am Heart J 2004;147:324-330.
 
10) Fiuzat M, et al:Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction. Results from the HF-ACTION (Heart Failure:A controlled trial investigating outcomes of exercise training) trial. J Am Coll Cardiol 2012;60:208-215.
 
11) Uretsky BF, et al:Randomized study assessing the eff ect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure:results of the PROVED trial. J Am Coll Cardiol 1993;22:955-962.
 
12) Packer M, et al:Withdrawal of digoxin from patients with chronic heart failure treatment with angiotensin-converting enzyme inhibitors. N Engl J Med 1993;329:1-7.
PubMed
13) The Digitalis Investigation Group:The eff ect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
 
14) Ebert AD, et al:Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphisms using a human induced pluripotent stem cell model system. Sci Transl Med 2014;6:255ra130.
PubMed
15) Li Y, et al:Mitochondria aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. J Clin Invest 2006;116:506-511.
 
16) Sun L, et al:ALDH2 activator inhibits increased myocardial infarction injury by nitroglycerin tolerance. Sci Transl Med 2011;3:107ra111.
PubMed
17) Brudi P, et al:Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potencystatin monotherapy in patients with a recent coronary event. Cardiology 2009;113:89-97.
PubMed
18) Dagli N, et al:The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 2007;30:230-235.
PubMed

Part 2 虚血性心疾患

P.60 掲載の参考文献
1) Ebert AD, et al:Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphisms using a human induced pluripotent stem cell model system. Sci Transl Med 2014;6:255ra130.
PubMed
2) Li Y, et al:Mitochondria aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. J Clin Invest 2006;116:506-511.
 
3) Leesar MA, et al:Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 2001;103:2935-2941.
PubMed
4) Brudi P, et al:Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potencystatin monotherapy in patients with a recent coronary event. Cardiology 2009;113:89-97.
PubMed
5) Dagli N, et al:The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 2007;30:230-235.
PubMed
6) Ridker PM, et al:Cardiovascular efficacy and safety of bococizumab in high-risk patients. E. Engl. J. Med 2017;376:1527-1539.
 

Part 3 高血圧

P.87 掲載の参考文献
1) Staessen JA, et al:Cardiovascular protection and blood pressure reduction:a metaanalysis. Lancet 2001;358:1305-1315.
PubMed
2) Lloyd-Jones DM, et al:Differential control of systolic and diastolic blood pressure:Factors associated with lack of blood pressure control in the community. Hypertension 2000;36:594-599.
PubMed
3) Materson BJ, et al:Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328(13):914-921.
 
4) Gupta AK, et al:Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents:a meta-analysis. Hypertension 2010;55(2):399-407.
PubMed
5) Williams B, et al:Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2):a randomized, double-blind crossover trial. Lancet 2015;386:2059-2068.
PubMed
6) Krum H, et al:Percutaneous renal denervation in patients with treatment-resistant hypertension:final 3-year report of the Symplicity HTN-1 study. Lancet 2014;383:622-629.
PubMed

Part 4 不整脈

P.124 掲載の参考文献
1) Risk stratification and survival after myocardial infarction. N Engl J Med 1983;309:331-336.
PubMed
2) Echt DS, et al:Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
 
3) Connolly SJ, et al:Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 2000;21:2071-2078.
PubMed
4) The AFFIRM Investigators:A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
 
5) The AFFIRM Investigators:Quality of life in atrial fibrillation:The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Am Heart J 2005;149:112-120.
PubMed
6) Haissaguerre M, et al:Spontaneous initiation of atrial fibrillation by ectopic beats originating in pulmonary veins. N Engl J Med 1998;339:659-666.
PubMed
7) Calkins H, et al:Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation. Two systemic literature reviews and meta-analysis. Circ Arrhythmia Electrophysiol 2009;2:349-361.
 
8) Packer DL, et al:Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation:The CABANA randomized clinical trial. JAMA 2019;321:1261-1274.
 
9) Marrouche NF, et al:Catheter ablation for atrial fibrillation with heart failure. N. Engl. J. Med 2018;378:417-427.
PubMed
10) Van Gelder LC, et al:Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-1373.
 
11) Washam JB, et al:Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes:a retrospective analysis of the Rivaroxaban once daily direct factor Xa inhibition compared with vitamin K antagonism of prevention of stroke and embolism trial in atrial fibrillation(ROCKET AF). Lancet 2015;283:2363-2370.
 
12) Turakhia MP, et al:Increased mortality associated with digoxin in contemporary patients with atrial fibrillation. Findings from the TREAT-AF study. J Cm Coll Cardiol 2014;64:660-668.
 
13) Ulimoen SR, et al:Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol 2013;111:225-230.
PubMed
14) Amino M, et al:Nifekalant hydrochloride and amiodarone hydrochloride result in similar improvements for 24-hour survival in cardiopulmonary arrest patients:The SOS-KANTO 2012 Study. J Cardiovasc Pharmacol 2015;66:600-609.
 

Part 5 血栓塞栓症

P.151 掲載の参考文献
1) Connolly SJ, et al:Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
PubMed
2) Granger CB, et al:Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
PubMed
3) Raber L, et al:Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents:A prospective cohort study. Circulation 2012;125:1110-1121.
PubMed
4) Dans AL, et al:Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2013;127:634-640.
PubMed
5) Okumura K, et al:Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular fibrillation. Clin Cardiol 2016 in press.
 

書評

最近チェックした商品履歴

Loading...